AIM ImmunoTech Inc.
AIM
$9.21
$0.9110.96%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -60.00% | -30.77% | -23.91% | 19.05% | -18.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.00% | -30.77% | -23.91% | 19.05% | -18.37% |
| Cost of Revenue | 25.00% | -41.67% | -73.33% | -- | -- |
| Gross Profit | -81.25% | -28.30% | 68.75% | 0.00% | -34.69% |
| SG&A Expenses | -32.25% | -60.59% | -43.39% | 1.61% | 69.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.05% | -58.06% | -44.85% | -31.96% | 32.92% |
| Operating Income | 36.89% | 58.19% | 44.97% | 32.36% | -33.50% |
| Income Before Tax | 36.31% | 52.55% | 52.66% | 62.60% | -58.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.31% | 52.55% | 52.66% | 62.60% | -58.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.31% | 52.55% | 52.66% | 62.60% | -58.89% |
| EBIT | 36.89% | 58.19% | 44.97% | 32.36% | -33.50% |
| EBITDA | 37.26% | 58.48% | 45.38% | 32.48% | -33.62% |
| EPS Basic | 55.19% | 63.76% | 60.05% | 65.78% | -55.49% |
| Normalized Basic EPS | 54.08% | 66.00% | 55.57% | 66.72% | -45.86% |
| EPS Diluted | 55.19% | 63.76% | 60.05% | 65.78% | -47.02% |
| Normalized Diluted EPS | 54.08% | 66.00% | 55.57% | 66.72% | -45.86% |
| Average Basic Shares Outstanding | 42.20% | 30.93% | 18.59% | 9.14% | 2.19% |
| Average Diluted Shares Outstanding | 42.20% | 30.93% | 18.59% | 9.14% | 2.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |